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ABSTRACT 26 
 27 
Setting: Cape Town, South Africa, where Xpert® MTB/RIF was introduced as a screening test for all 28 
presumptive tuberculosis (TB) cases in primary health services.  29 
 30 
Study Aim: To compare laboratory costs of smear/culture- and Xpert MTB/RIF-based TB diagnostic 31 
algorithms in routine operational conditions. 32 
 33 
Methods: Economic costing was undertaken from a laboratory perspective. We used an ingredients-based 34 
costing approach with test costs based on the cost per unit and quantities utilised for buildings, equipment, 35 
consumables, staff and overheads. Cost allocation was based on reviews of standard operating procedures 36 
and laboratory records, observation and timing of test procedures, measurement of laboratory areas and 37 
manager interviews. We analysed electronic laboratory test data to compare overall costs and cost per 38 
pulmonary TB and MDR-TB case diagnosed. All costs were expressed as 2013 CPI-adjusted values.  39 
 40 
Results: Total TB diagnostic costs increased by 43% from $440,967 in the smear-culture-based algorithm 41 
(April-June 2011) to $632,262 in the Xpert-based algorithm (April-June 2013). The cost per TB case 42 
diagnosed increased by 157% from $48.77 to $125.32 with 1601 and 1281 cases diagnosed respectively. 43 
The total cost per MDR-TB case diagnosed was similar at $190.14 and $183.86 in respective algorithms and 44 
the number of cases diagnosed increased by 13%, from 95 to 107. 45 
 46 
Conclusion: The introduction of the Xpert-based algorithm resulted in substantial cost increases. This was 47 
not matched by the expected increase in TB diagnostic efficacy, calling into question the sustainability of this 48 
expensive new technology. 49 
50 
INTRODUCTION 51 
 52 
New molecular diagnostic tests for tuberculosis (TB) such as GenoType® MTBDRplus line probe assay 53 
(Hain LifeScience GmbH, Nehren, Germany) (LPA) and Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA) 54 
(Xpert) hold the promise of improving TB and multidrug-resistant (MDR)-TB diagnosis as both are sensitive 55 
and faster than culture and conventional drug susceptibility tests (DST). The accuracy of these tests is well 56 
established from laboratory and demonstration studies1,2. A meta-analysis of ten LPA studies showed high 57 
sensitivity (98.1% (95% CI 95.9 to 99.1)) and specificity (98.7% (95% CI  97.3 to 99.4)) for rifampicin 58 
resistance and lower, more variable sensitivity of 84.3% (95% CI 76.6 to 89.8) and specificity of 99.5% (95% 59 
CI 97.5 to 99.9) for isoniazid resistance3. A Cochrane Review of fifteen studies where Xpert was used as the 60 
initial test replacing smear microscopy, showed a pooled sensitivity of 88% (95%CrI 83% to 92%) and 61 
specificity of 98% (95% CrI 97% to 99%) for detecting Mycobacterium tuberculosis (MTB). In eleven of these 62 
studies, pooled sensitivity was 94% (95% CrI 87% to 97%) and specificity 98% (95% CrI 97% to 99%) for 63 
rifampicin resistance4. 64 
 65 
Policy recommendations5,6 have been based mainly on accuracy data from laboratory and demonstration 66 
studies7–9. However demonstration studies tend not to reflect the realities of a test being used within an 67 
operational context8,9. There is a tendency to over-estimate effectiveness partly due to greater resource 68 
availability than would be found in routine settings8. Insufficient emphasis is placed on costs and an over-69 
estimate of effectiveness may provide a more optimistic view of cost-effectiveness than would be found in 70 
routine settings. 71 
 72 
Cost estimates are essential to making decisions on the most effective use of limited resources. One of the 73 
challenges to evaluating costs and cost-effectiveness is the lack of standard accepted evaluation 74 
methods10,11. Current guidelines are too broad and generalised and poor adherence to guidelines contributes 75 
to the failure to provide consistent and comparable cost data to policy makers12. For example, two studies in 76 
South Africa reported Xpert costs of $25.90 (in 2010 $US)13 and $14.93 (in 2012 US$)14 respectively. 77 
Differences in costs were partly attributable to the exclusion of cartridge shipping costs and specimen 78 
transport costs in the latter.   79 
 80 
 A guideline on laboratory costs15 emphasises the importance of an ingredients-based approach to costing 81 
that includes all resource elements, including quality assurance and control. It emphasises the need to 82 
accurately allocate overhead costs and deal with capital assets in a way that takes “time preference” into 83 
account  i.e. that $1 in 2 years is worth less than $1 today, reflecting a societal and individual preference to 84 
have money and resources today rather than in the future. Capital costs need to be discounted to reflect this 85 
preference16.        86 
 87 
Xpert is an expensive test and making the case for additional expenditure requires empirical data to 88 
supplement the estimates used in decision-making. Operational data can help improve the reliability of 89 
estimates used in cost and cost-effectiveness analyses and is particularly important in high-burden settings 90 
with resource constraints.  91 
 92 
The aim of this study was to compare laboratory costs for the diagnosis of pulmonary TB and MDR-TB in a 93 
new Xpert-based algorithm to that in the previous smear/culture-based algorithm within a routine operational 94 
context. The study was part of a PROVE IT (Policy Relevant Outcomes from Validating Evidence on ImpacT) 95 
evaluation (http://www.treattb.org/) to assess the impact of new molecular diagnostic tests. 96 
 97 
METHODS 98 
 99 
Setting 100 
The study was undertaken in Cape Town, South Africa, a city with a high TB and MDR-TB burden with 101 
28,644 TB cases (752/100,000 population) and 1,020 MDR-TB cases notified in 2011. In comparison, 102 
25,846 TB cases (663/100,000 population) and 1,134 MDR-TB cases were notified in 2013. Human 103 
immunodeficiency virus (HIV) co-infection rates amongst TB cases were 47% (97% tested) and 44% (98% 104 
tested) in respective years (Source: J. Caldwell, Routine TB Programme Data, Cape Town Health 105 
Directorate, April 2016).   106 
 107 
Free TB diagnostic services were provided at 142 primary health care facilities in eight sub-districts. All 108 
sputum specimens collected at primary health care facilities were sent by courier to the National Health 109 
Laboratory Services (NHLS). Test results were entered into a networked, electronic laboratory database. 110 
 111 
TB diagnostic algorithms 112 
A smear/culture-based algorithm (Figure 1) was used in the “comparator” period (April to June 2011=T1). All 113 
presumptive TB cases were evaluated by smear microscopy from two spot sputum specimens, taken 1-hour 114 
apart. In high MDR-TB risk cases (>four weeks previous TB treatment, from congregate settings or with an 115 
MDR-TB contact), the second specimen underwent liquid culture (BACTEC™ MGIT™ 960) and drug 116 
susceptibility testing (DST) using the  GenoType® MTBDRplus line probe assay (LPA) and second line 117 
testing as required. Smear-negative, HIV-infected, low MDR-TB risk cases were required to submit a third 118 
specimen for culture. 119 
 120 
An Xpert-based algorithm was used in the “intervention” period (April to June 2013=T2) with Xpert replacing 121 
smear microscopy for all presumptive TB cases (Figure 1). Two sputum specimens were evaluated: the first 122 
was tested with Xpert; if MTB was detected the second underwent smear microscopy. In HIV-infected cases 123 
with negative Xpert tests, the second specimen underwent culture. Confirmatory LPA and second line DST 124 
were undertaken for cases with rifampicin resistance. 125 
 126 
Costing methods 127 
Economic costing was undertaken from a laboratory perspective for the high throughput central laboratory in 128 
Cape Town. Only costs related to the dedicated TB laboratory were assessed. Costs were calculated from 129 
the time the courier collected specimens from health facilities to the time results were returned. Costs were 130 
assessed only for pulmonary TB (PTB) tests for smear, culture, LPA and Xpert.  131 
 132 
An excel-based costing tool was developed, based on that used in the Foundation for Innovation and 133 
Development (FIND) GenoType® MTBDRplus demonstration study. We used an ingredients-based costing 134 
approach with test costs based on the cost per unit and quantities utilised for buildings, equipment, 135 
consumables, staff and overheads. Cost allocation was determined by reviews of standard operating 136 
procedures and laboratory records, direct observation and timing of the test procedures outlined in Figure 2, 137 
measurement of laboratory areas used for test processes and interviews with managers. Quality assurance 138 
samples were included in batch costs and outputs adjusted accordingly. 139 
 140 
Building costs per square metre, including air-conditioning and consoles, were provided by the Council for 141 
Scientific and Industrial Research for a Level 2 laboratory for 2013. Equipment and consumables costs were 142 
sourced from laboratory financial records and quotes from suppliers for 2013. These costs were corrected by 143 
the consumer price index (CPI) to derive 2011 costs17. Staff and overheads costs were provided from 144 
laboratory financial records for both years. Overhead costs included costs for buildings, equipment, 145 
consumables and staff involved in specimen sorting and registration, results processing, procurement, 146 
stores, training, supervision and management. Specimen transport, electricity, water, sanitation, municipal 147 
and biohazardous waste disposal, cleaning and janitorial services, security services and telephone and 148 
internet costs were also included. Further information on costs is provided in online appendices 1, 2 and 3.   149 
 150 
Building and equipment costs were spread over their expected lifespan and discounted to present values at 151 
a “risk-free” rate of 3%11,18 with maintenance based on expenditure or estimated at 10% of annual costs. 152 
Laboratory utilisation was based on a 10-hour weekday for 21 days per month and a 4-hour Saturday shift. 153 
The cost of staff time was based on a 40-hour week for 46 weeks of the year with efficiency estimated at 154 
80%. 155 
 156 
All costs were calculated in local currency (ZAR). For comparative purposes, 2011 costs were expressed as 157 
2013 CPI-adjusted values and converted to US$ based on average United Nations treasury operational rates 158 
in 2013 (ZAR9.75 = US$1.00)19. 159 
 160 
Study population and analysis 161 
All sputum specimens processed in the laboratory in T1 (smear/culture-based algorithm) and T2 (Xpert-162 
based algorithm) and resources related to the processing of these specimens were included in the 163 
assessment of laboratory and test costs. Overall laboratory costs were based on the cost per test and test 164 
volumes for microscopy (bleach-treated specimens), microscopy and culture, LPA and Xpert.   165 
 166 
We used laboratory data for presumptive PTB cases from five of the eight sub-districts to estimate the cost 167 
per TB and MDR-TB case diagnosed. These sub-districts were included in a prior analysis of TB yield and 168 
their selection criteria have been described elsewhere20. The analysis required the full sequence of tests 169 
undertaken for presumptive TB cases. We therefore identified cases with specimens submitted in May 2011 170 
and May 2013 and linked all diagnostic tests from the preceding and following months to identify the full 171 
sequence of tests undertaken for each case. Linkage was undertaken with MS-SQL using a combination of 172 
facility name, patient folder number, name, surname and age or birth-date.  173 
 174 
We defined a TB case as an individual with one or more smears positive and / or culture positive for MTB 175 
and / or MTB detected on Xpert. An MDR-TB case was defined as an individual with rifampicin resistance on 176 
LPA or Xpert. We compared the mean cost per patient diagnosed with TB and MDR-TB in each algorithm. 177 
MDR-TB costs were reported as additional to a TB diagnosis.  178 
 179 
Ethics statement 180 
The Health Research Ethics Committee at Stellenbosch University (IRB0005239) (N10/09/308) and Ethics 181 
Advisory Group at The International Union Against Tuberculosis and Lung Disease (59/10) approved the 182 
study. A waiver of informed consent was granted for use of routine data. The City of Cape Town Health 183 
Directorate, Western Cape Health Department and National Health Laboratory Service granted permission to 184 
use routine health data. 185 
 186 
RESULTS 187 
 188 
Comparison of total laboratory costs and activities 189 
In T1, 79,544 specimens were tested at the central laboratory compared to 59,238 in T2. The majority (96% 190 
and 94% respectively) were for PTB tests.  191 
 192 
Total laboratory costs for PTB tests increased from $440,967 in T1 to $632,262 in T2 (Table 1). Costs for 193 
bleach treated smears decreased by 49% from $128,916 to $65,799; smear and culture costs decreased by 194 
35% from $247,771 to $161,707 and LPA by 50% from $64,279 to $32,339, all driven by decreased test 195 
volumes. The increase in total cost was attributable to Xpert test which accounted for 59% of total laboratory 196 
costs in the Xpert-based algorithm.  197 
 198 
Annual overhead costs increased by 12% from $137,101 in T1 to $153,628 in T2. The largest contributors to 199 
the increase were specimen transport costs, utilities, biohazardous waste and janitorial services (Online 200 
Appendix 3). Overhead costs were allocated based on test volume as this was identified as the key driver for 201 
these costs. Overhead costs per test were increased by 47% from $1.80 in the smear/culture-based 202 
algorithm to $2.63 in the Xpert-based algorithm, due to both increases in overhead costs and reductions in 203 
test volumes.   204 
 205 
Comparison of test costs (Table 1) 206 
Smear microscopy costs (per bleach-treated specimen) increased from $2.85 in the smear/culture-based 207 
algorithm to $3.70 in the Xpert-based algorithm. Overhead costs were the main driver, accounting for 63% of 208 
costs in the smear/culture-based algorithm and 71% in the Xpert-based algorithm.  209 
 210 
Microscopy and culture costs (per sodium hydroxide/sodium citrate-treated specimen) increased from 211 
$8.75 in the smear/culture-based algorithm to $9.62 per test in the Xpert-based algorithm. Consumables 212 
(44% and 40% in respective algorithms), staff costs (25% and 23% respectively) and overheads (21% and 213 
27% respectively) were the key cost drivers. The highest cost component for consumables was for BACTEC 214 
MGIT tubes and supplement.  215 
 216 
MTBDRPlus Line Probe Assay costs per test were similar at $16.12 in the smear/culture-based algorithm 217 
and $16.98 per test in the Xpert-based algorithm. Most tests were done on culture isolates and culture costs 218 
have not been included in these totals. Consumables were the greatest cost-driver (79% and 75% in 219 
respective algorithms) due mostly to the cost of the GenoType® MTBDRplus kit. 220 
 221 
Xpert MTB/RIF cost per test was $19.03. The largest cost driver was consumables (77%), due mostly to the 222 
cost of the XpertMTB/RIF cartridges.    223 
 224 
Cost per TB case diagnosed 225 
In May 2011 7,842 presumptive TB cases were tested through the smear/culture-based algorithm. The full 226 
sequence of tests for these individuals included 10,472 bleach-treated microscopy tests, 5,347 sodium 227 
hydroxide/sodium citrate-treated microscopy and culture tests and 980 tests for MTB culture confirmation at 228 
a total cost of $78,080. The mean cost per TB case diagnosed (n = 1601) was $48.77 (Table 2).  229 
 230 
In May 2013 7,714 presumptive TB cases were tested through the Xpert-based algorithm. The full sequence 231 
of tests for these individuals included 2,711 bleach-treated microscopy tests, 3,689 sodium 232 
hydroxide/sodium citrate-treated microscopy and culture tests, 431 tests for MTB culture confirmation and 233 
6,009 Xpert tests at a total cost of $160,536. The mean cost per TB case diagnosed (n = 1281) was $125.32.  234 
 235 
The cost per TB case is influenced by the proportion of TB cases identified, which decreased in the Xpert-236 
based algorithm (probably due to a decline in prevalence – see discussion for further details). We assessed 237 
a scenario where TB diagnostic yield in the Xpert-based algorithm was similar to that in the smear/culture-238 
based algorithm which reduced the cost per TB case diagnosed to $101.94.   239 
 240 
Cost per MDR-TB case diagnosed 241 
There were 833 LPA tests done for TB cases in the smear/culture-based algorithm at a cost of $13,430 and 242 
mean additional cost per MDR-TB case (n = 95) of $141.37 (Table 2). In comparison 369 LPA tests were 243 
done amongst TB cases in the Xpert-based algorithm at a cost of $6,264 and mean additional cost per MDR-244 
TB case (n=107) of $58.54. When these costs were added to the “base” cost of the TB diagnosis, the total 245 
cost per MDR-TB case diagnosed was $190.14 in the smear-culture-based algorithm compared to $183.86 246 
in the Xpert-based algorithm.  247 
 248 
As our prior analysis showed no difference in TB yield between the algorithms20, we apportioned all 249 
additional costs to the additional MDR-TB cases diagnosed. This produced an incremental cost-250 
effectiveness ratio (ICER) of $6,274 per additional MDR-TB case diagnosed. 251 
 252 
DISCUSSION 253 
 254 
The use of the more sensitive Xpert test4,21,22 as a replacement for smear microscopy was expected to 255 
increase the number of TB cases diagnosed and simultaneous drug-susceptibility screening for all 256 
presumptive TB cases (not only those at high MDR-TB risk) expected to increase the number of MDR-TB 257 
cases diagnosed. A modelling study in South Africa, estimated that at full coverage Xpert would increase 258 
annual TB diagnostic costs by 53-57% to $48-70 million per year but that this would be partially off-set by a 259 
30% to 37% increase in TB and 69 to 71% increase in MDR-TB cases diagnosed annually23. 260 
 261 
Our study found a 43% increase in PTB laboratory costs, from $440,967 in the smear-culture-based 262 
algorithm to $632,262 in the Xpert-based algorithm for 3-month periods. However, the increase in laboratory 263 
costs was not matched by an increase in TB diagnostic efficacy. Although the number of presumptive TB 264 
cases evaluated was similar in the smear/culture (n=7842) and Xpert-based algorithms (n=7714), the 265 
proportion of TB cases diagnosed (yield) decreased from 20.4% (n=1601) to 16.6% (n=1281). A prior 266 
stepped-wedge analysis undertaken as part of PROVE IT for 2010-2013 showed a temporal decline in TB 267 
diagnostic yield in both algorithms20. This may have been partly attributable to a declining TB prevalence, 268 
due perhaps to the rapid scale-up of anti-retroviral treatment in South Africa. When estimates were adjusted 269 
for the temporal trend, the study showed no significant difference in TB yield between the algorithms.  270 
 271 
The increase in total costs and decrease in number of cases identified in the current study increased the cost 272 
per TB case diagnosed by 157% from $48.77 in the smear/culture-based algorithm to $125.32 in the Xpert-273 
based algorithm. On the other hand, even a scenario with a similar proportion of TB cases identified in the 274 
Xpert-based algorithm to that in the smear/culture-based algorithm would increase the cost per TB case 275 
diagnosed by 109% (to $101.94).  276 
 277 
The cost per MDR-TB case diagnosed was similar at $190.14 in the smear/culture based algorithm and 278 
$183.86 in the Xpert-based algorithm. In the smear and culture-based algorithm, drug susceptibility testing 279 
was only undertaken in high MDR-TB risk presumptive TB cases. One of the advantages of Xpert is that it 280 
provides simultaneous screening for TB and rifampicin resistance. The use of Xpert for all presumptive TB 281 
cases contributed to the 13% increase in the number of MDR-TB cases identified. Whilst these additional 282 
cases may have been diagnosed later in the smear/culture-based algorithm (i.e. after 1st line treatment 283 
failed), early diagnosis potentially reduces transmission, avoids the amplification of drug resistance and 284 
reduces patient morbidity and mortality. This modest benefit has to be weighed against the heavy overall 285 
expenditure, as shown by the MDR-TB ICER of $6,274. This figure needs to be viewed with some caution as 286 
possible changes in TB and thus MDR-TB prevalence has not been taken into consideration. Additional 287 
studies are required to assess whether Xpert or other drug susceptibility tests can be targeted more cost-288 
effectively.  289 
 290 
The cost-effectiveness of newly introduced laboratory tests is influenced by how services are re-organised 291 
and whether under-utilised assets can be redeployed. In the short-term it may be difficult to reduce costs 292 
until new systems and workloads are well established; however in the future efforts could be made to reduce 293 
overhead costs. Overhead costs per test could be reduced by increasing test volumes (through additional 294 
case-finding efforts for example). However, consumable costs were by far the greatest cost-drivers – 295 
accounting for 40% and 60% of total costs in respective algorithms. It remains to be seen whether global 296 
increases in test volumes or the availability of generic tests can reduce these costs substantially.   297 
 298 
Strengths and limitations  299 
The major strength of the analysis was that we collected detailed information to accurately estimate the cost 300 
per TB and MDR-TB case diagnosed. By including the full sequence of tests undertaken for individuals we 301 
reflected the real-life variation found in diagnostic practices, including for example additional culture testing 302 
for smear and Xpert-negative cases in respective algorithms.      303 
 304 
The extent to which our results can be generalised is limited by the setting as Cape Town has a relatively 305 
good laboratory and health infrastructure. Additional evidence is required from poorly-resourced settings 306 
including where culture is not available (as the benefit of Xpert may be greater in areas previously using only 307 
smear microscopy) and from rural settings (where specimen transport costs may be higher, economies of 308 
scale cannot be readily achieved and expertise may differ). The possible difference in TB prevalence 309 
between the two time-periods is a limitation, and has been taken into consideration in the analysis. The 310 
analysis was undertaken from a laboratory perspective only; the impact of new molecular diagnostic tests on 311 
patient costs is important and has been reported elsewhere24. 312 
 313 
Implications for policy and practice 314 
The increase in total laboratory costs is in a similar range to that projected by two South African studies13,23. 315 
However we did not find the expected increases in TB-yield. Our findings are in keeping with a national study 316 
showing an 8% decrease in the number of laboratory confirmed PTB cases from 2011 to 2012, despite the 317 
introduction of Xpert25. Even when temporal trends of a possible declining prevalence were taken into 318 
account in our study, increased costs were not matched with increased TB diagnostic efficacy. It is difficult to 319 
justify the increased laboratory costs incurred through the introduction of Xpert and cost implications should 320 
not be underestimated. If the $160,411 spent on TB diagnosis in the Xpert-based algorithm was used for 321 
testing as per the smear/culture-based algorithm, the number of presumptive TB cases screened could have 322 
been increased by over 100% (from 7,714 to 16,158).  323 
 324 
There is strong impetus to increase the use of Xpert. To mid-2014, 7.5 million Xpert cartridges were procured 325 
internationally with more than half being procured by South Africa26. However, the broader impact of Xpert 326 
remains questionable. Although studies have reported early TB21,27,28 and MDR-TB29,30 treatment initiation, 327 
Xpert had no impact on TB morbidity and mortality27,31,32. This together with the increased costs warrants a 328 
review of the role of Xpert in TB diagnosis.  329 
 330 
Having invested heavily in this new technology, a reversion to a smear/culture-based algorithm is unlikely. 331 
Thus either technical adjustments need to be sought to improve Xpert sensitivity and / or the price of Xpert 332 
has to be substantially reduced to improve cost-effectiveness in our setting. Urgent efforts need to be made 333 
to optimise costs through improved efficiency of the Xpert-based algorithm, including exploring alternative 334 
options. Theron et al, for example, showed that pre-screening with smear reduced the cost of a TB diagnosis 335 
in their model by more than 20%33. A discrete event simulation model has been developed and validated as 336 
part of PROVE IT and will be used to evaluate more cost-effective diagnostic options.   337 
 338 
This study highlights the need for thorough costing during early implementation to inform scale-up. As new 339 
diagnostic technologies become available, consideration should also be given to the wider costs of serial 340 
implementation of different technologies, overlapping of different technologies and redundancies that are 341 
created when existing technologies are also retained9.   342 
 343 
CONCLUSION 344 
 345 
Economic costing is a key component in the decision to implement new TB diagnostic tests and careful 346 
consideration should be given to cost implications, particularly in resource-constrained, high-burden settings. 347 
The introduction of the Xpert-based algorithm has resulted in substantial increases in cost which are in line 348 
with modelling exercises undertaken in South Africa. However these were not matched by an increase in TB 349 
diagnostic efficacy; massive cost increases persist even when temporal trends of a possible declining TB 350 
prevalence were taken into consideration. One of the benefits of the Xpert-based algorithm was the modest 351 
increase in the number of MDR-TB cases diagnosed, which comes at high cost.   352 
 353 
In view of the limited benefits, we have serious concerns about the sustainability of this expensive, new 354 
technology. More sensitive tests that are comparable to culture and that are substantially cheaper than Xpert 355 
(at current prices) are required, particularly if TB screening is to be substantially scaled up as suggested by 356 
the draft Global Plan to Stop TB 2016-202034. 357 
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486 
Table 1: Comparison of test costs in the smear/culture and Xpert-based algorithms 487 
 488 
Test costs and volumes are for the central National Health Laboratory only. Total laboratory costs were $440,967 in the 489 
smear-culture-based algorithm compared to $632,262 in the Xpert-based algorithm for respective 3-month periods. All 490 
costs are expressed in 2013 CPI-adjusted values. 491 
 492 
493 
  Smear 
microscopy 
(Bleach 
treated) 
Smear 
microscopy 
& culture 
Culture 
confirmation 
MTBDRPlus 
Line Probe 
Assay 
Xpert 
MTBRif 
Smear/culture-
based algorithm  
(April – June 
2011)(T1) 
Building space $0.02 $0.14 $0.05 $0.15 - 
Equipment $0.11 $0.72 $0.02 $0.17 - 
Consumables $0.36 $3.87 $0.84 $12.67 - 
Staff  $0.55 $2.21 $0.57 $1.34 - 
Overheads  $1.80 $1.80 $0.00 $1.80 - 
Cost per test $2.85 $8.75 $1.49 $16.12 - 
Number of tests 45 252 27 508 4 747 3 987 - 
Total costs $128 916 $240 706 $7 065 $64 279 - 
Xpert-based 
algorithm  
(April – June 
2013)(T2) 
Building space $0.02 $0.14 $0.05 $0.15 $0.06 
Equipment $0.13 $0.74 $0.02 $0.18 $0.40 
Consumables $0.36 $3.87 $0.84 $12.67 $14.62 
Staff  $0.55 $2.21 $0.57 $1.34 $1.32 
Overheads  $2.64 $2.64 $0.00 $2.64 $2.64 
Cost per test $3.70 $9.62 $1.49 $16.98 $19.03 
Number of tests 17 770 16 503 2 020 1 905 19 565 
Total costs $65 799 $158 700 $3 007 $32 339 $372 418 
Table 2: Costs per pulmonary TB and MDR-TB case diagnosed in the smear/culture and Xpert-based algorithms 494 
 495 
 
Costs in the 
smear/culture-based 
algorithm 
Costs in the Xpert-
based algorithm 
Changes with the Xpert-
based algorithm 
Smear microscopy 
(Bleach treated) 
$29 833.23 
(n=10,472) 
$10 038.29 
(n=2,711) 
-$19 794.94 
Smear microscopy & culture 
(Sodium hydroxide/sodium 
citrate-treated) 
$46 788.44 
(n=5,347) 
$35 475.12 
(n=3,689) 
-$11 313.32 
Culture confirmation $1 458.51 
(n=980) 
$641.53 
(n=431) 
-$816.98 
Xpert MTB Rif  _ $114 380.73 
(n=6,009) 
$114 380.73 
 
Total TB diagnostic costs $78 080.18 $160 535.67 $82 455.50 
Number of presumptive TB 
cases evaluated 
7 842 7 714 -128 
Number TB cases identified 1 601 1 281 -320 
Mean cost per TB case 
identified 
$48.77 $125.32 $76.55 
Total costs for MTBDRPlus 
Line Probe Assay 
$13 429.75 
(n = 833) 
$6 264.02 
(n = 369) 
-$7 165.73 
Number of MDR-TB cases 
diagnosed 
95 107 12 
Mean additional cost per 
MDR-TB case diagnosed  
$141.37 $58.54 -82.82 
Mean total cost per         
MDR-TB case diagnosed 
$190.14 $183.86 -$6.27 
 496 
  497 
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Figure 1: Testing protocols in TB diagnostic algorithms 
 
        Smear/culture-based algorithm            Xpert-based algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The simplified sequence of diagnostic tests in each algorithm and the action taken based on test results is shown. Abbreviations: TB - tuberculosis; LPA – Genotype MTBDRPlus line 
probe assay; DST - drug susceptibility testing; HIV – human immunodeficiency virus; MTB – mycobacterium tuberculosis. Reprinted from: Naidoo P, Dunbar R, Lombard C, du Toit E 
Caldwell J et al. Comparing tuberculosis diagnostic yield in smear/culture and Xpert® MTB/RIF-based algorithms using a non-randomised stepped-wedge design. PLoS One. 
2016;11(3):e0150487.
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Figure 2: Laboratory workflow and test processes  
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